IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT

NCT03696537 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Extreme toxicity

Conditions

Acute Myeloid Leukemia
Chronic Myeloid Leukemia
Acute Lymphocytic Leukemia
Myelodysplastic Syndromes

Interventions

DRUG: Fludarabine
RADIATION: Total Marrow Irradiation (TMI)

Sponsor

Naoyuki G. Saito, M.D., Ph.D.

Collaborators

[object Object]